Data Sharing in the Pharmaceutical Enterprise: The Genie's Out of the Bottle

This Commentary shows that the present emphasis on the sharing of data from clinical trials can be extended to the entire pharmaceutical enterprise. The authors constructed a Data Sharing Dashboard that shows the relationship between all of the life-cycle domains of the pharmaceutical enterprise fro...

Full description

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2017-09, Vol.39 (9), p.1890-1894
Main Authors: Beninger, Paul, Connelly, James, Natarajan, Chandrasekhar
Format: Article
Language:English
Subjects:
Computational Biology
Data retrieval
data sharing
Databases, Factual
Drug Industry
exposure effect relationship
Information Dissemination
outcomes research
pharmaceutical enterprise
Pharmaceuticals
Public-Private Sector Partnerships
R&D
Research & development
structure activity relationship
Studies
target discovery
Technology assessment
Zika virus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This Commentary shows that the present emphasis on the sharing of data from clinical trials can be extended to the entire pharmaceutical enterprise. The authors constructed a Data Sharing Dashboard that shows the relationship between all of the life-cycle domains of the pharmaceutical enterprise from discovery to obsolescence and the domain-bridging disciplines, such as target credentialing, structure-activity relationships, and exposure-effect relationships. The published literature encompassing the pharmaceutical enterprise is expansive, covering the major domains of discovery, translation, clinical development, and post-marketing outcomes research, all of which have even larger, though generally inaccessible, troves of legacy data bases. Notable exceptions include the fields of genomics and bioinformatics. We have the opportunity to broaden the present momentum of interest in data sharing to the entire pharmaceutical enterprise, beginning with discovery and extending into health technology assessment and post-patent expiry generic use with the plan of integrating new levels and disciplines of knowledge and with the ultimate goal of improving the care of our patients.
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2017.08.001